PL3115372T3 - Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania - Google Patents

Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania

Info

Publication number
PL3115372T3
PL3115372T3 PL16182420T PL16182420T PL3115372T3 PL 3115372 T3 PL3115372 T3 PL 3115372T3 PL 16182420 T PL16182420 T PL 16182420T PL 16182420 T PL16182420 T PL 16182420T PL 3115372 T3 PL3115372 T3 PL 3115372T3
Authority
PL
Poland
Prior art keywords
fusion proteins
lysosomal enzyme
targeted therapeutic
enzyme fusion
therapeutic lysosomal
Prior art date
Application number
PL16182420T
Other languages
English (en)
Inventor
Mika Aoyagi-Scharber
Teresa Margaret Christianson
Melita Dvorak-Ewell
Daniel Wendt
Shinong Long
Jonathan Lebowitz
Daniel Solomon Gold
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of PL3115372T3 publication Critical patent/PL3115372T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/65Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105Alpha-N-acetylglucosaminidase (3.2.1.50)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL16182420T 2012-11-27 2013-11-27 Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania PL3115372T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261730378P 2012-11-27 2012-11-27
US201361788968P 2013-03-15 2013-03-15
EP16182420.6A EP3115372B1 (en) 2012-11-27 2013-11-27 Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
PCT/US2013/072287 WO2014085621A1 (en) 2012-11-27 2013-11-27 Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
EP13802834.5A EP2925776B1 (en) 2012-11-27 2013-11-27 Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
PL3115372T3 true PL3115372T3 (pl) 2019-09-30

Family

ID=49753532

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16182420T PL3115372T3 (pl) 2012-11-27 2013-11-27 Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania
PL13802834T PL2925776T3 (pl) 2012-11-27 2013-11-27 Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13802834T PL2925776T3 (pl) 2012-11-27 2013-11-27 Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania

Country Status (26)

Country Link
US (8) US9376480B2 (pl)
EP (2) EP2925776B1 (pl)
JP (2) JP6831176B2 (pl)
KR (4) KR102262882B1 (pl)
CN (1) CN104822701B (pl)
AR (1) AR093626A1 (pl)
AU (1) AU2013352184B2 (pl)
BR (1) BR112015012152B1 (pl)
CA (1) CA2892146A1 (pl)
CL (1) CL2015001371A1 (pl)
CY (1) CY1122555T1 (pl)
DK (2) DK2925776T3 (pl)
ES (2) ES2729997T3 (pl)
HR (2) HRP20181351T1 (pl)
HU (2) HUE039334T2 (pl)
IL (3) IL238824B (pl)
LT (1) LT3115372T (pl)
MX (2) MX367024B (pl)
PL (2) PL3115372T3 (pl)
PT (2) PT3115372T (pl)
RS (1) RS58916B1 (pl)
RU (1) RU2680581C2 (pl)
SI (1) SI3115372T1 (pl)
TW (2) TWI626250B (pl)
WO (1) WO2014085621A1 (pl)
ZA (1) ZA201503509B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170698T1 (hr) * 2008-05-07 2017-09-22 Biomarin Pharmaceutical Inc. Lizosomski usmjereni peptidi i njihove uporabe
HUE039334T2 (hu) 2012-11-27 2018-12-28 Biomarin Pharm Inc Célzott terápiás lizoszómális enzim fúziós fehérjék és azok alkalmazásai
HK1222093A1 (zh) * 2013-05-15 2017-06-23 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
JP6623213B2 (ja) * 2014-08-11 2019-12-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド リソソーム酵素に融合したマンノース−6−リン酸含有ペプチド
EP3197503A4 (en) * 2014-09-25 2018-05-16 The General Hospital Corporation Cell-based targeted delivery of pseudonomas exotoxin
US10556015B2 (en) 2014-10-24 2020-02-11 Criteo S.A. Lysosomal targeting of enzymes, and uses thereof
TWI752907B (zh) 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
CN107849131A (zh) 2015-07-06 2018-03-27 瑞泽恩制药公司 多特异性抗原结合分子及其用途
HK1253529A1 (zh) 2015-11-06 2019-06-21 Biomarin Pharmaceutical Inc. 用於检测中和溶酶体酶的摄取的抗体或其它因子的基於细胞的测定
RU2751235C2 (ru) * 2016-02-24 2021-07-12 Байомарин Фармасьютикал Инк. Терапевтические слитые белки направленного действия на основе лизосомных ферментов, соответствующие составы и их применения
SG11201808176TA (en) 2016-04-15 2018-10-30 The Trustees Of The Univ Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
CL2016003282A1 (es) 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington
EP3635009A1 (en) 2017-06-07 2020-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
CA3076036A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
SG11202002730XA (en) 2017-10-02 2020-04-29 Denali Therapeutics Inc Fusion proteins comprising enzyme replacement therapy enzymes
IL322464A (en) 2018-02-07 2025-09-01 Regeneron Pharma Methods and compositions for administering therapeutic protein
CA3092961A1 (en) * 2018-03-09 2019-09-12 Avrobio, Inc. Compositions and methods for treating parkinson's disease
BR112020021962A2 (pt) 2018-04-30 2021-01-26 Amicus Therapeutics, Inc. construtos para terapia gênica e métodos de uso
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
EP3802619A1 (en) 2018-06-08 2021-04-14 F. Hoffmann-La Roche AG Peptidic linker with reduced post-translational modification
US11097015B2 (en) 2018-10-10 2021-08-24 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
AU2019381803A1 (en) * 2018-11-16 2021-06-10 AskBio Inc. Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal targeting sequence
WO2021072372A1 (en) * 2019-10-10 2021-04-15 Amicus Therapeutics, Inc. Variant igf2 constructs
WO2021133822A1 (en) 2019-12-24 2021-07-01 Juvena Therapeutics,Inc. Regenerative polypeptides and uses thereof
WO2021183895A1 (en) 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
CA3223707A1 (en) 2021-06-21 2022-12-29 Hanadie Yousef Regenerative polypeptides and uses thereof
WO2022271981A2 (en) 2021-06-23 2022-12-29 Lycia Therapeutics, Inc. Bifunctional compounds containing igf-2 polypeptides
CN117343197A (zh) * 2021-10-15 2024-01-05 中山大学 重组融合抗体
KR20250160369A (ko) * 2023-01-27 2025-11-12 리제너론 파마슈티칼스 인코포레이티드 변형된 랩도바이러스 당단백질 및 이의 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
AUPN674895A0 (en) 1995-11-23 1995-12-14 Women's And Children's Hospital Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
DE10035433C2 (de) 2000-07-20 2002-07-18 Tuma Wolfgang Schonende Hochanreicherung von fetalen Zellen aus pripherem Blut und Verwendung derselben
ES2300439T3 (es) 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
CA2463473A1 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Targeted therapeutic proteins
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
EP1514106A4 (en) 2002-05-29 2007-05-09 Zystor Therapeutics Inc TARGETED THERAPEUTIC PROTEINS
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CN1922313B (zh) 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
US7678371B2 (en) 2005-03-04 2010-03-16 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
HRP20170698T1 (hr) 2008-05-07 2017-09-22 Biomarin Pharmaceutical Inc. Lizosomski usmjereni peptidi i njihove uporabe
US8697654B2 (en) * 2008-12-18 2014-04-15 E I Du Pont De Nemours And Company Peptide linkers for effective multivalent peptide binding
US9029530B2 (en) 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
EP2475376B1 (en) * 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
MX362176B (es) 2010-06-25 2019-01-07 Amcor Rigid Plastics Usa Llc Sistema de depuracion de oxigeno para un recipiente.
MX2013000324A (es) * 2010-06-25 2013-02-01 Shire Human Genetic Therapies Tratamiento del sindrome de sanfilippo tipo b.
WO2012088461A2 (en) * 2010-12-23 2012-06-28 Biogen Idec Inc. Linker peptides and polypeptides comprising same
JP6175372B2 (ja) * 2011-03-04 2017-08-02 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ポリペプチド組成物用ペプチドリンカーおよびその使用方法
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
WO2012122477A1 (en) * 2011-03-10 2012-09-13 Novozymes A/S Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
HUE039334T2 (hu) 2012-11-27 2018-12-28 Biomarin Pharm Inc Célzott terápiás lizoszómális enzim fúziós fehérjék és azok alkalmazásai

Also Published As

Publication number Publication date
HK1216026A1 (en) 2016-10-07
US20160031964A1 (en) 2016-02-04
MX367024B (es) 2019-08-02
ES2729997T3 (es) 2019-11-07
MX2019009191A (es) 2019-10-09
WO2014085621A1 (en) 2014-06-05
IL238824A0 (en) 2015-06-30
IL272854B (en) 2021-07-29
HRP20190918T1 (hr) 2019-09-20
JP2016505539A (ja) 2016-02-25
LT3115372T (lt) 2019-06-25
BR112015012152A2 (pt) 2017-08-15
US20190225666A1 (en) 2019-07-25
AU2013352184A1 (en) 2015-06-04
AU2013352184B2 (en) 2018-05-31
KR20150088317A (ko) 2015-07-31
RU2680581C2 (ru) 2019-02-22
PT3115372T (pt) 2019-06-12
MX2015006644A (es) 2015-08-10
US9771408B2 (en) 2017-09-26
MX377150B (es) 2025-03-07
CY1122555T1 (el) 2021-01-27
CL2015001371A1 (es) 2015-10-09
ES2679374T3 (es) 2018-08-24
US9834587B2 (en) 2017-12-05
DK3115372T3 (da) 2019-06-11
IL272854A (en) 2020-04-30
KR102262882B1 (ko) 2021-06-10
IL262976A (en) 2018-12-31
US20220127326A1 (en) 2022-04-28
KR20220047892A (ko) 2022-04-19
EP2925776B1 (en) 2018-05-30
SI3115372T1 (sl) 2019-08-30
US9376480B2 (en) 2016-06-28
CN104822701B (zh) 2018-09-21
HUE039334T2 (hu) 2018-12-28
US9834588B2 (en) 2017-12-05
IL262976B (en) 2020-02-27
US20160039900A1 (en) 2016-02-11
IL238824B (en) 2018-11-29
US10301369B2 (en) 2019-05-28
HRP20181351T1 (hr) 2018-11-02
DK2925776T3 (en) 2018-09-03
HUE043679T2 (hu) 2019-09-30
RS58916B1 (sr) 2019-08-30
EP3115372A1 (en) 2017-01-11
AR093626A1 (es) 2015-06-17
PT2925776T (pt) 2018-07-30
CN104822701A (zh) 2015-08-05
TW201827468A (zh) 2018-08-01
CA2892146A1 (en) 2014-06-05
US20170355744A1 (en) 2017-12-14
JP2019206556A (ja) 2019-12-05
TW201431884A (zh) 2014-08-16
ZA201503509B (en) 2016-11-30
US20160031963A1 (en) 2016-02-04
RU2015125491A (ru) 2017-01-10
US11254725B2 (en) 2022-02-22
JP6831176B2 (ja) 2021-02-17
KR20230054482A (ko) 2023-04-24
US20140161788A1 (en) 2014-06-12
TWI626250B (zh) 2018-06-11
US9845346B2 (en) 2017-12-19
TWI711632B (zh) 2020-12-01
PL2925776T3 (pl) 2018-11-30
BR112015012152B1 (pt) 2023-04-25
JP6913719B2 (ja) 2021-08-04
EP2925776A1 (en) 2015-10-07
KR102385392B1 (ko) 2022-04-11
EP3115372B1 (en) 2019-03-06
KR20210070389A (ko) 2021-06-14
KR102521039B1 (ko) 2023-04-12
US20160031965A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
IL272854B (en) Medicinal lysosomal enzyme chimeric proteins and their uses
IL272855A (en) New and used KIF5B–RET fusion compounds
PT3489254T (pt) Proteínas de fusão direcionadas/imunomoduladoras e seus métodos de fabrico
IL236809A0 (en) Interleukin-10 fusion proteins and their use
PT3744835T (pt) Proteínas de fusão modificadoras do adn e métodos de utilização das mesmas
IL279676A (en) Recombinant proteins and therapeutic uses
IL236933A0 (en) Interleukin-2 fusion proteins and their use
PT2718440T (pt) Proteína que tem atividade de nuclease, proteínas de fusão e utilizações das mesmas
EP2785837A4 (en) TARGETED ENZYMATIC COMPOUNDS AND ITS USES
IL229753A0 (en) Proteins that release relaxin and their use
IL222382A0 (en) Robo1-fc fusion protein and use thereof for treating tumours
EP2880050A4 (en) NOVEL ENZYMES, ENZYME COMPONENTS AND USES THEREOF
SG11201403852UA (en) Fused pyrroledicarboxamides and their use as pharmaceuticals
EP2718432A4 (en) NUCLEASE FUSION PROTEIN AND USES THEREOF
GB2523211B (en) MCT protein inhibitor-related prognostic and therapeutic methods
EP2536741A4 (en) THERAPY TARGETING FUSIONS OF GENES
AU2012901619A0 (en) Fusion Proteins and Use Thereof
AU2011902431A0 (en) Fusion Proteins and Use Thereof
AU2011905077A0 (en) Radiotracers and Therapeutic Agents